ヨーロッパの遺伝子検査市場
Market Size in USD Billion
CAGR :
% 
 予測期間 |
2022 –2029 |
 市場規模（基準年） |
USD 4,344.02 Billion |
 Market Size (Forecast Year) |
USD 12,730.46 Billion |
 CAGR |
% |
| 主要市場プレーヤー |
ヨーロッパの遺伝子検査市場、タイプ別（キャリア検査、診断検査、出生前検査、新生児スクリーニング、予測および発症前検査、その他のタイプ）、技術別（DNAシーケンシング（NGSベースの検査）、ポリメラーゼ連鎖反応、マイクロアレイ、全ゲノムシーケンシング、蛍光in situハイブリダイゼーション（FISH）、その他）、疾患別（希少遺伝性疾患、がん、嚢胞性線維症、鎌状赤血球貧血、デュシェンヌ型筋ジストロフィー、サラセミア、ハンチントン病、脆弱X症候群、デュシェンヌ型筋ジストロフィー、その他）、エンドユーザー別（病院、診療所、診断センター、民間診療所、検査サービスプロバイダー、民間研究所）業界動向と2029年までの予測
市場分析と洞察
ヨーロッパの遺伝子検査市場は、遺伝性疾患の有病率の高さ、遺伝子検査市場における需要を高める技術進歩の進展、市場の成長につながる研究開発への投資増加などの要因によって牽引されています。現在、先進国と新興国全体で医療費が増加しており、メーカーが新しい革新的な遺伝子検査市場を開発するための競争上の優位性を生み出すことが期待されています。ただし、遺伝子検査に関連するコストの高さと遺伝子検査に対する厳格な規制枠組みがあります。
ヨーロッパの遺伝子検査市場レポートは、市場シェア、新開発、製品パイプライン分析、国内および現地の市場プレーヤーの影響、新たな収益源、市場規制の変更、製品承認、戦略的決定、製品発売、地理的拡大、市場における技術革新の観点から見た機会の分析の詳細を提供します。分析と市場シナリオを理解するには、アナリスト概要についてお問い合わせください。当社のチームが、収益に影響を与えるソリューションを作成し、目的の目標を達成するお手伝いをします。さまざまな地域の発展途上国における小売ユニットの拡張性と事業拡大、および機械および医薬品製品の安全な流通のためのサプライヤーとのパートナーシップは、予測期間における市場の需要を推進した主な原動力です。
市場の定義
遺伝子検査は、遺伝子、染色体、またはタンパク質の変化を特定する医療検査の一種です。遺伝子検査の結果は、疑わしい遺伝的疾患を確認または除外したり、遺伝性疾患を発症または遺伝させる可能性を判断するのに役立ちます。現在、77,000 を超える遺伝子検査が使用されており、さらに新しい検査が開発されています。
革新と技術の増加、市場参入者数の増加、そして斬新な製品の発売も、ヨーロッパの遺伝子検査市場の成長を促進しています。
ヨーロッパの遺伝子検査市場は、2022年から2029年の予測期間に市場成長が見込まれています。データブリッジマーケットリサーチは、市場は2022年から2029年の予測期間に14.6%のCAGRで成長し、2021年の43億4,402万米ドルから2029年には127億3,046万米ドルに達すると分析しています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2022年から2029年 |
|
基準年 |
2021 |
|
歴史的な年 |
2020 |
|
定量単位 |
収益（百万米ドル） |
|
対象セグメント |
タイプ別（保因者検査、診断検査、出生前検査、新生児スクリーニング、予測および発症前検査、その他のタイプ）、技術別（DNAシーケンシング（NGSベースの検査）、ポリメラーゼ連鎖反応、マイクロアレイ、全ゲノムシーケンシング、蛍光in situハイブリダイゼーション（FISH）、その他）、疾患別（希少遺伝性疾患、がん、嚢胞性線維症、鎌状赤血球貧血、デュシェンヌ型筋ジストロフィー、サラセミア、ハンチントン病、脆弱X症候群、デュシェンヌ型筋ジストロフィー、その他）、エンドユーザー別（病院、診療所、診断センター、民間診療所、検査サービスプロバイダー、民間研究所） |
|
対象国 |
ドイツ、フランス、イギリス、イタリア、スペイン、ロシア、トルコ、ベルギー、オランダ、スイス、その他のヨーロッパ諸国 |
|
対象となる市場プレーヤー |
Thermo Fisher Scientific Inc.、Bio-Rad Laboratories, Inc.、PerkinElmer Inc.、Illumina, Inc.、QIAGEN、F. Hoffmann-La Roche Ltd.、Myriad Genetics, Inc.、Abbott、Eurofins Scientific、Biocartis、Cepheid（Danaherの子会社）、PacBio、BioReference、Natera, Inc.など |
ヨーロッパの遺伝子検査市場の動向
ドライバー
- 遺伝性疾患の増加
例えば、
- 2019年1月に発表された「欧州乳がん評議会宣言2018：乳がんの遺伝的リスク予測検査」によると、BRCA1/2検査はがん検査の適応として英国および他のヨーロッパ地域で広く普及していることが示されています。
- 欧州連合では組織的な遺伝子検査プログラムが提供されており、高品質のスクリーニングサービスが国民に提供されることが保証されています。
したがって、遺伝子検査市場の需要が高まっています。
- 次世代シーケンシングの採用増加
ゲノミクスに焦点を当てた薬理学がさまざまな慢性疾患、特に癌の治療において大きな役割を果たし続けるにつれて、次世代シーケンシング (NGS) は、個々の腫瘍や特定の受容体の分子基盤に対するより深く正確な洞察を提供する強力なツールとして進化しています。
NGS は、従来の方法に比べて精度、感度、速度の面で優れており、腫瘍学の分野に大きな影響を与える可能性があります。NGS では 1 回のアッセイで複数の遺伝子を評価できるため、原因となる変異を特定するために複数のテストを注文する必要がなくなります。
例えば、
- NGS は、薬物動態学および薬力学に関連する薬理遺伝学の包括的なプロファイリングにも利用されてきました。2017 年の初期レポートでは、このテクノロジーがこれらの遺伝子の一般的な遺伝子変異とまれな遺伝子変異の両方を発見するための信頼性が高く効率的なツールとなる可能性があることが示唆されています。
したがって、これが遺伝子検査市場の成長の原動力となることが期待されます。
機会
-
研究開発の強化
例えば、
-
2020年に発表された「世界における臨床ゲノムシーケンシングの利用可能性と資金調達」という報告書によると、英国以外のヨーロッパ諸国のほとんどで、NGS（次世代シーケンシング）とゲノム医療の成長を促進するための遺伝子検査の利用可能性が高まっていることが示されています。
-
可処分所得の増加
国が医療に費やす費用とその長期にわたる成長率は、資金調達の取り決めや医療制度の組織構造など、さまざまな経済的および社会的要因によって左右されます。特に、国の総所得レベルとその国の国民が医療に費やす金額の間には強い関連性があります。
また、主要な市場プレーヤーが講じる戦略的取り組みは、2022年から2029年の予測期間に遺伝子検査市場に構造的完全性と将来の機会をもたらすでしょう。
制約/課題
- 遺伝子検査の高額な費用
遺伝子検査は高額になる可能性があり、一部の健康保険ではカバーされない場合があります。遺伝子検査は数多くありますが、検査対象となる疾患によって費用が異なります。
Breastcancer.orgによると、がんの遺伝子検査の費用は大きく異なり、300ドルから5,000ドルの範囲です。遺伝子検査の費用は、検査の種類と複雑さによって異なります。
遺伝子検査の費用は、検査の性質と複雑さに応じて、100 ドルから 2,000 ドル以上までさまざまです。有意な結果を得るために複数の検査が必要な場合や、多数の家族メンバーを検査する必要がある場合は、費用が高くなります。新生児スクリーニングの費用は州によって異なります。
欧州の遺伝子検査市場へのCOVID-19の影響
COVID-19は市場にプラスの影響を与えており、多くの遺伝子検査や血清学的検査がCOVID-19に対して実施され、この期間中に遺伝子検査の需要が高まっています。
最近の開発
- 2021年12月、サーモフィッシャーサイエンティフィック社は、バイオ医薬品およびバイオテクノロジー業界向けの臨床研究サービスの世界的大手プロバイダーであるPPD社を174億ドルで買収したことを発表しました。この買収により、収益が増加し、市場の成長が促進されました。
ヨーロッパの遺伝子検査市場の範囲
ヨーロッパの遺伝子検査市場は、タイプ、技術、疾患、エンドユーザーに分類されています。これらのセグメントの成長は、業界のわずかな成長セグメントの分析に役立ち、ユーザーに貴重な市場概要と市場洞察を提供し、コア市場アプリケーションを特定するための戦略的決定を下すのに役立ちます。
タイプ
- 診断検査
- 出生前検査
- 新生児スクリーニング
- 予測的および発症前検査
- キャリアテスト
- その他のタイプ
タイプに基づいて、ヨーロッパの遺伝子検査市場は、診断検査、出生前検査、新生児スクリーニング、予測および発症前検査、保因者検査、およびその他のタイプに分類されます。
テクノロジー
- ポリメラーゼ連鎖反応
- DNA シーケンシング (NGS ベースのテスト)
- 全ゲノム配列解析
- マイクロアレイ
- 蛍光in situハイブリダイゼーション（FISH）
- その他
技術に基づいて、ヨーロッパの遺伝子検査市場は、DNA シーケンシング (NGS ベースの検査)、ポリメラーゼ連鎖反応、マイクロアレイ、全ゲノムシーケンシング、蛍光 in situ ハイブリダイゼーション (FISH)、その他に分類されます。
病気
- 癌
- 鎌状赤血球貧血
- サラセミア
- 稀な遺伝性疾患
- 脆弱X症候群
- デュシェンヌ型筋ジストロフィー
- ハンチントン病
- 嚢胞性線維症
- その他
疾患に基づいて、ヨーロッパの遺伝子検査市場は、希少遺伝性疾患、がん、嚢胞性線維症、鎌状赤血球貧血、デュシェンヌ型筋ジストロフィー、サラセミア、ハンチントン病、脆弱X症候群、その他に分類されます。
エンドユーザー
- 病院
- クリニック
- 診断センター
- 個人クリニック
- 検査サービスプロバイダー
- 民間研究室
エンドユーザーに基づいて、ヨーロッパの遺伝子検査市場は、病院、診療所、診断センター、民間診療所、検査サービスプロバイダー、民間検査機関に分類されます。
遺伝子検査市場の地域分析/洞察
遺伝子検査市場が分析され、市場規模の洞察と傾向が、上記のように国、タイプ、技術、疾患、エンドユーザー別に提供されます。
ドイツは、これらの国の人口における遺伝性疾患の蔓延により、市場における主要な支配国となっています。また、市場シェアと市場収益の面で遺伝子検査市場を支配しており、予測期間中もその優位性は拡大し続けるでしょう。これは、地域の人口における遺伝的欠陥と染色体異常によるもので、急速な研究開発が市場を後押ししています。
レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。新規および交換販売、国の人口統計、疾病疫学、輸出入関税などのデータ ポイントは、個々の国の市場シナリオを予測するために使用される主要な指標の一部です。さらに、国別データの予測分析を提供する際には、グローバル ブランドの存在と可用性、地元および国内ブランドとの激しい競争により直面する課題、販売チャネルの影響が考慮されています。
競争環境と遺伝子検査市場シェア分析
遺伝子検査市場の競争状況は、競合他社に関する詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、遺伝子検査市場における会社の重点にのみ関連しています。
遺伝子検査市場で活動している主要企業としては、サーモフィッシャーサイエンティフィック社、イルミナ社、キアゲン社、F.ホフマン・ラ・ロシュ社、ミリアドジェネティクス社、アボット社、ユーロフィンサイエンティフィック社、バイオカルティス社、セフェイド社（ダナハー社の子会社）、パックバイオ社、バイオリファレンス社、ナテラ社などが挙げられます。
研究方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。市場データは、市場統計モデルとコヒーレント モデルを使用して分析および推定されます。さらに、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数の市場への影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。これとは別に、データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、企業市場シェア分析、測定基準、世界対地域、ベンダー シェア分析が含まれます。さらに質問がある場合は、アナリストへの電話をリクエストしてください。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE GENETIC TESTING MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 STRATEGIC INITIATIVES:
4.4 CONCLUSION:
4.5 INDUSTRY INSIGHTS
4.5.1 CANCER GENETICS RISK ASSESSMENT AND COUNSELING
4.5.2 GENETIC TESTS PRICING
4.5.3 KEY INSIGHTS
5 EPIDERMIOLOGY
6 EUROPE GENETIC TESTING MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING PREVALENCE OF GENETIC DISORDERS
7.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING
7.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY A MAJOR PLAYER
7.1.4 INCREASE TREND TOWARD PERSONALIZED MEDICATION
7.2 RESTRAINTS
7.2.1 HIGH COST OF GENETIC TESTING
7.2.2 CYBER SECURITY CONCERNS IN GENOMICS
7.3 OPPORTUNITIES
7.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER
7.3.2 TECHNOLOGICAL ADVANCEMENT
7.3.3 INCREASING RESEARCH AND DEVELOPMENT
7.3.4 RISING DISPOSABLE INCOME
7.4 CHALLENGES
7.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM GENETIC TESTING
7.4.2 STRINGENT REGULATION POLICY
8 EUROPE GENETIC TESTING MARKET, BY TYPE
8.1 OVERVIEW
8.2 DIAGNOSTIC TESTING
8.3 PRENATAL TESTING
8.3.1 NON-INVASIVE SCREENING
8.3.1.1 BY SCREENING METHOD
8.3.1.1.1 WHOLE GENOME SEQUENCING
8.3.1.1.2 COUNTING OF CFDNA FRAGMENTS
8.3.1.1.3 OTHERS
8.3.1.2 BY CONDITION
8.3.1.2.1 TRISOMY 21
8.3.1.2.2 KLINEFELTER SYNDROME
8.3.1.2.3 JACOBS SYNDROME
8.3.1.2.4 CYSTIC FIBROSIS
8.3.1.2.5 TURNER SYNDROME
8.3.1.2.6 TRISOMY 18
8.3.1.2.7 HEMOPHILIA
8.3.1.2.8 TRISOMY 13
8.3.1.2.9 MICRODELETION SYNDROME
8.3.1.2.10 FETAL GENDER
8.3.1.2.11 OTHERS
8.3.1.3 BY SCREENING TYPE
8.3.1.3.1 CARRIER SEQUENCING
8.3.1.3.2 SEQUENTIAL SEQUENCING
8.3.2 MATERNAL SERUM QUAD SCREENING
8.4 NEW BORN SCREENING
8.4.1.1 SICKLE CELL DISEASE
8.4.1.2 CONGENITAL HYPOTHYROIDISM
8.4.1.3 PHENYLKETONURIA (PKU)
8.4.1.4 GALACTOSEMIA
8.4.1.5 MAPLE SYRUP URINE DISEASE
8.4.1.6 OTHERS
8.5 PREDICTIVE AND PRESYMPTOMATIC TESTING
8.6 CARRIER TESTING
8.6.1 BY TEST TYPE
8.6.1.1 MOLECULAR SCREENING TEST
8.6.1.2 BIOCHEMICAL SCREENING TEST
8.6.2 BY TYPE
8.6.2.1 EXPANDED CARRIER SCREENING
8.6.2.1.1 PREDESIGNED PANEL TESTING
8.6.2.1.2 CUSTOM-MADE PANEL TESTING
8.6.2.2 TARGETED DISEASE CARRIER SCREENING
8.6.2.2.1 BY MEDICAL CONDITION
8.6.2.2.2 HEMATOLOGICAL CONDITIONS
8.6.2.2.3 PULMONARY CONDITIONS
8.6.2.2.4 NEUROLOGICAL CONDITIONS
8.6.2.2.5 OTHER CONDITIONS
8.7 OTHER TYPES
9 EUROPE GENETIC TESTING MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 POLYMERASE CHAIN REACTION
9.2.1 REAL-TIME PCR (QPCR)
9.2.2 DIGITAL PCR (DPCR)
9.2.3 REVERSE TRANSCRIPTION PCR (RT-PCR)
9.2.4 HOT-START PCR
9.2.5 MULTIPLEX PCR
9.2.6 OTHER PCR
9.3 DNA SEQUENCING (NGS-BASED TESTING)
9.3.1 NEXT GENERATION SEQUENCING (NGS)
9.3.2 SANGER SEQUENCING (SINGLE GENE)
9.3.3 OTHER
9.4 WHOLE GENOME SEQUENCING
9.5 MICROARRAYS
9.5.1 DNA MICROARRAYS
9.5.2 PROTEIN MICROARRAYS
9.5.3 OTHER MICROARRAYS
9.6 FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
9.7 OTHERS
10 EUROPE GENETIC TESTING MARKET, BY DISEASES
10.1 OVERVIEW
10.2 CANCER
10.2.1 BREAST
10.2.2 COLON
10.2.3 LUNG
10.2.4 PROSTATE
10.2.5 OTHERS
10.3 SICKLE CELL ANEMIA
10.4 THALASSEMIA
10.5 RARE GENETIC DISORDER
10.5.1 TRISOMY 21
10.5.2 MONOSOMY X
10.5.3 TRISOMY 13
10.5.4 MICRODELETION SYNDROME
10.5.5 TRISOMY 18
10.5.6 OTHERS
10.6 FRAGILE X SYNDROME
10.7 DUCHENNE MUSCULAR DYSTROPHY
10.8 HUNTINGTON'S DISEASE
10.9 CYSTIC FIBROSIS
10.1 OTHERS
11 EUROPE GENETIC TESTING MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 CLINICS
11.4 DIAGNOSTIC CENTERS
11.5 PRIVATE CLINICS
11.6 LABORATORY SERVICE PROVIDERS
11.7 PRIVATE LABORATORIES
12 EUROPE GENETIC TESTING MARKET, BY REGION
12.1 EUROPE
12.1.1 GERMANY
12.1.2 FRANCE
12.1.3 U.K.
12.1.4 RUSSIA
12.1.5 ITALY
12.1.6 SPAIN
12.1.7 TURKEY
12.1.8 NETHERLANDS
12.1.9 SWITZERLAND
12.1.10 BELGIUM
12.1.11 REST OF EUROPE
13 EUROPE GENETIC TESTING MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: EUROPE
14 WOT ANALYSIS
15 COMPANY PROFILE
15.1 ILLUMINA, INC.
15.1.1 COMPANY SNAPSHOT
15.1.2 COMPANY SHARE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENT
15.1.4.1 ACQUISITION
15.1.4.2 COLLABORATION
15.2 CEPHEID
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.2.5.1 BUSINEES EXPANSION
15.3 FULGENT GENETICS
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENT
15.3.5.1 ACQUISITION
15.4 PERKINELMER INC.
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.4.5.1 PRODUCT LAUNCH
15.5 THERMO FISHER SCIENTIFIC INC.
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.5.5.1 COLLABORATION
15.6 ABBOTT
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 BIOCARTIS
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.7.4.1 PARTNERSHIP
15.7.4.2 AGREEMENT
15.8 BIO-HELIX
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 BIO-RAD LABORATORIES, INC.
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.9.4.1 ACQUISITION
15.9.4.2 PARTNERSHIP
15.1 BIOREFERENCE
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.10.4.1 ACQUISITION
15.11 ELITECHGROUP
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENTS
15.11.3.1 PRODUCT LAUNCH
15.11.3.2 BUSINESS EXPANSION
15.12 EUROFINS SCIENTIFIC
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.12.4.1 PRODUCT LAUNCH
15.13 EUGENE LABS
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 F. HOFFMANN-LA ROCHE LTD)
15.14.1 COMPANY SNAPSHOT
15.14.2 REVENUE ANALYSIS (PARENT COMPANY)
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENTS
15.14.4.1 PRODUCT LAUNCH
15.15 GENES2ME
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 INVITAE CORPORATION
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENTS
15.17 MAPMYGENOME
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
15.18 MEDGENOME
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENT
15.19 MYRIAD GENETICS
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENT
15.2 NATERA, INC.
15.20.1 COMPANY SNAPSHOT
15.20.2 PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENT
15.20.3.1 PARTNERSHIP
15.21 OTOGENRTICS
15.21.1 COMPANY SNAPSHOT
15.21.2 PRODUCT PORTFOLIO
15.21.3 RECENT DEVELOPMENT
15.22 PACBIO
15.22.1 COMPANY SNAPSHOT
15.22.2 REVENUE ANALYSIS
15.22.3 PRODUCT PORTFOLIO
15.22.4 RECENT DEVELOPMENT
15.23 QIAGEN
15.23.1 COMPANY SNAPSHOT
15.23.2 PRODUCT PORTFOLIO
15.23.3 RECENT DEVELOPMENTS
15.23.3.1 PARTNERSHIP
15.23.3.2 PRODUCT LAUNCH
15.24 SEMA4 OPCO, INC.
15.24.1 COMPANY SNAPSHOT
15.24.2 REVENUE ANALYSIS
15.24.3 PRODUCT PORTFOLIO
15.24.4 RECENT DEVELOPMENT
15.25 SORENSON GENOMICS
15.25.1 COMPANY SNAPSHOT
15.25.2 PRODUCT PORTFOLIO
15.25.3 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
表のリスト
TABLE 1 EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 3 EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 4 EUROPE DIAGNOSTIC TESTING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 7 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 8 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 9 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 10 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 11 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 12 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 13 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 14 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 15 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 16 EUROPE NEW BORN SCREENING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 18 EUROPE PREDICTIVE AND PRESYMPTOMATIC TESTING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 21 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 22 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 23 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 24 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 25 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 26 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 27 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 28 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 29 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 30 EUROPE OTHER TYPES IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 EUROPE GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 32 EUROPE POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 EUROPE POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 34 EUROPE DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 EUROPE DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 36 EUROPE WHOLE GENOME SEQUENCING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 EUROPE MICROARRAYS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 EUROPE MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 39 EUROPE FLUORESCENCE IN SITU HYBRIDIZATION (FISH) IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 EUROPE OTHERS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 EUROPE GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 42 EUROPE CANCER IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 43 EUROPE CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 44 EUROPE SICKLE CELL ANEMIA IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 45 EUROPE THALASSEMIA IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 46 EUROPE RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 47 EUROPE RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 48 EUROPE FRAGILE X SYNDROME IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 49 EUROPE DUCHENNE MUSCULAR DYSTROPHY IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 50 EUROPE HUNTINGTON'S DISEASE IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 51 EUROPE CYSTIC FIBROSIS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 52 EUROPE OTHERS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 53 EUROPE GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 54 EUROPE HOSPITALS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 55 EUROPE CLINICS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 56 EUROPE DIAGNOSTIC CENTERS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 57 EUROPE PRIVATE CLINICS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 58 EUROPE LABORATORY SERVICE PROVIDERS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 59 EUROPE PRIVATE LABORATORIES IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 60 EUROPE GENETIC TESTING MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 61 EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 63 EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 64 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 66 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 67 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 68 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 69 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 70 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 71 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 72 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 73 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 74 EUROPE NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 75 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 76 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 77 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 78 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 80 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 81 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 83 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 84 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 85 EUROPE GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 86 EUROPE POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 87 EUROPE DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 88 EUROPE MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 89 EUROPE GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 90 EUROPE RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 91 EUROPE CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 92 EUROPE GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 93 GERMANY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 94 GERMANY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 95 GERMANY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 96 GERMANY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 GERMANY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 98 GERMANY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 99 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 100 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 101 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 102 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 103 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 104 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 105 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 106 GERMANY NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 107 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 108 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 109 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 110 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 112 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 113 GERMANY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 GERMANY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 115 GERMANY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 116 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 117 GERMANY GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 118 GERMANY POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 119 GERMANY DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 120 GERMANY MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 121 GERMANY GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 122 GERMANY RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 123 GERMANY CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 124 GERMANY GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 125 FRANCE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 126 FRANCE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 127 FRANCE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 128 FRANCE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 129 FRANCE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 130 FRANCE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 131 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 132 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 133 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 134 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 135 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 136 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 137 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 138 FRANCE NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 139 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 140 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 141 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 142 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 143 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 144 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 145 FRANCE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 146 FRANCE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 147 FRANCE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 148 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 149 FRANCE GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 150 FRANCE POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 151 FRANCE DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 152 FRANCE MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 153 FRANCE GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 154 FRANCE RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 155 FRANCE CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 156 FRANCE GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 157 U.K. GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 158 U.K. GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 159 U.K. GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 160 U.K. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 161 U.K. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 162 U.K. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 163 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 164 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 165 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 166 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 167 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 168 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 169 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 170 U.K. NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 171 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 172 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 173 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 174 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 175 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 176 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 177 U.K. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 178 U.K. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 179 U.K. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 180 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 181 U.K. GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 182 U.K. POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 183 U.K. DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 184 U.K. MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 185 U.K. GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 186 U.K. RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 187 U.K. CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 188 U.K. GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 189 RUSSIA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 190 RUSSIA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 191 RUSSIA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 192 RUSSIA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 193 RUSSIA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 194 RUSSIA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 195 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 196 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 197 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 198 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 199 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 200 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 201 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 202 RUSSIA NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 203 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 204 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 205 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 206 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 207 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 208 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 209 RUSSIA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 210 RUSSIA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 211 RUSSIA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 212 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 213 RUSSIA GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 214 RUSSIA POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 215 RUSSIA DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 216 RUSSIA MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 217 RUSSIA GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 218 RUSSIA RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 219 RUSSIA CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 220 RUSSIA GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 221 ITALY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 222 ITALY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 223 ITALY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 224 ITALY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 225 ITALY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 226 ITALY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 227 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 228 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 229 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 230 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 231 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 232 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 233 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 234 ITALY NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 235 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 236 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 237 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 238 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 239 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 240 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 241 ITALY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 242 ITALY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 243 ITALY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 244 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 245 ITALY GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 246 ITALY POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 247 ITALY DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 248 ITALY MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 249 ITALY GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 250 ITALY RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 251 ITALY CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 252 ITALY GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 253 SPAIN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 254 SPAIN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 255 SPAIN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 256 SPAIN PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 257 SPAIN PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 258 SPAIN PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 259 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 260 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 261 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 262 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 263 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 264 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 265 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 266 SPAIN NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 267 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 268 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 269 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 270 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 271 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 272 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 273 SPAIN EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 274 SPAIN EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 275 SPAIN EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 276 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 277 SPAIN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 278 SPAIN POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 279 SPAIN DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 280 SPAIN MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 281 SPAIN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 282 SPAIN RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 283 SPAIN CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 284 SPAIN GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 285 TURKEY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 286 TURKEY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 287 TURKEY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 288 TURKEY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 289 TURKEY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 290 TURKEY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 291 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 292 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 293 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 294 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 295 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 296 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 297 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 298 TURKEY NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 299 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 300 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 301 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 302 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 303 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 304 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 305 TURKEY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 306 TURKEY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 307 TURKEY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 308 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 309 TURKEY GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 310 TURKEY POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 311 TURKEY DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 312 TURKEY MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 313 TURKEY GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 314 TURKEY RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 315 TURKEY CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 316 TURKEY GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 317 NETHERLANDS GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 318 NETHERLANDS GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 319 NETHERLANDS GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 320 NETHERLANDS PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 321 NETHERLANDS PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 322 NETHERLANDS PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 323 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 324 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 325 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 326 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 327 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 328 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 329 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 330 NETHERLANDS NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 331 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 332 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 333 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 334 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 335 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 336 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 337 NETHERLANDS EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 338 NETHERLANDS EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 339 NETHERLANDS EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 340 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 341 NETHERLANDS GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 342 NETHERLANDS POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 343 NETHERLANDS DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 344 NETHERLANDS MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 345 NETHERLANDS GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 346 NETHERLANDS RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 347 NETHERLANDS CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 348 NETHERLANDS GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 349 SWITZERLAND GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 350 SWITZERLAND GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 351 SWITZERLAND GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 352 SWITZERLAND PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 353 SWITZERLAND PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 354 SWITZERLAND PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 355 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 356 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 357 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 358 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 359 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 360 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 361 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 362 SWITZERLAND NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 363 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 364 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 365 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 366 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 367 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 368 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 369 SWITZERLAND EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 370 SWITZERLAND EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 371 SWITZERLAND EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 372 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 373 SWITZERLAND GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 374 SWITZERLAND POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 375 SWITZERLAND DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 376 SWITZERLAND MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 377 SWITZERLAND GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 378 SWITZERLAND RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 379 SWITZERLAND CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 380 SWITZERLAND GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 381 BELGIUM GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 382 BELGIUM GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 383 BELGIUM GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 384 BELGIUM PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 385 BELGIUM PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 386 BELGIUM PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 387 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 388 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 389 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 390 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 391 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 392 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 393 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 394 BELGIUM NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 395 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 396 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 397 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 398 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 399 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 400 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 401 BELGIUM EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 402 BELGIUM EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 403 BELGIUM EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 404 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 405 BELGIUM GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 406 BELGIUM POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 407 BELGIUM DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 408 BELGIUM MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 409 BELGIUM GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 410 BELGIUM RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 411 BELGIUM CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 412 BELGIUM GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 413 REST OF EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 414 REST OF EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 415 REST OF EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
図表一覧
FIGURE 1 EUROPE GENETIC TESTING MARKET: SEGMENTATION
FIGURE 2 EUROPE GENETIC TESTING MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE GENETIC TESTING MARKET: DROC ANALYSIS
FIGURE 4 EUROPE GENETIC TESTING MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE GENETIC TESTING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE GENETIC TESTING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE GENETIC TESTING MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE GENETIC TESTING MARKET: APPLICATION COVERAGE GRID
FIGURE 9 EUROPE GENETIC TESTING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE GENETIC TESTING MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF LYMPHEDEMA AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE EUROPE GENETIC TESTING MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 DIAGNOSTIC TESTING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE GENETIC TESTING MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE GENETIC TESTING MARKET AND ASIA-PACIFIC EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE GENETIC TESTING MARKET
FIGURE 15 EUROPE GENETIC TESTING MARKET: BY TYPE, 2021
FIGURE 16 EUROPE GENETIC TESTING MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 17 EUROPE GENETIC TESTING MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 18 EUROPE GENETIC TESTING MARKET: BY TYPE, LIFELINE CURVE
FIGURE 19 EUROPE GENETIC TESTING MARKET: BY TECHNOLOGY, 2021
FIGURE 20 EUROPE GENETIC TESTING MARKET: BY TECHNOLOGY, 2022-2029 (USD MILLION)
FIGURE 21 EUROPE GENETIC TESTING MARKET: BY TECHNOLOGY, CAGR (2022-2029)
FIGURE 22 EUROPE GENETIC TESTING MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 23 EUROPE GENETIC TESTING MARKET: BY DISEASES, 2021
FIGURE 24 EUROPE GENETIC TESTING MARKET: BY DISEASES, 2022-2029 (USD MILLION)
FIGURE 25 EUROPE GENETIC TESTING MARKET: BY DISEASES, CAGR (2022-2029)
FIGURE 26 EUROPE GENETIC TESTING MARKET: BY DISEASES, LIFELINE CURVE
FIGURE 27 EUROPE GENETIC TESTING MARKET: BY END USER, 2021
FIGURE 28 EUROPE GENETIC TESTING MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 29 EUROPE GENETIC TESTING MARKET: BY END USER, CAGR (2022-2029)
FIGURE 30 EUROPE GENETIC TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 31 EUROPE GENETIC TESTING MARKET: SNAPSHOT (2021)
FIGURE 32 EUROPE GENETIC TESTING MARKET: BY COUNTRY (2021)
FIGURE 33 EUROPE GENETIC TESTING MARKET: BY COUNTRY (2022 & 2029)
FIGURE 34 EUROPE GENETIC TESTING MARKET: BY COUNTRY (2021 & 2029)
FIGURE 35 EUROPE GENETIC TESTING MARKET: BY TYPE (2022-2029)
FIGURE 36 EUROPE GENETIC TESTING MARKET: COMPANY SHARE 2021 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
